Skip to main content
    N

    Nexgel Inc (NXGL)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $3.93
    +0.05 (+1.29%)

    Market Cap: $2.08M

    Last updated: Nov 17, 2026 at 10:58 AM ET

    Nexgel Inc (NXGL) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Nexgel (NXGL) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Nexgel reported EPS of -$1.60, above the -$4.80 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    24%(5/21)
    Avg Surprise
    -45.52%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$4.08
    RangeN/A
    3 analysts
    Revenue Consensus
    $5.37M
    Range$5.16M - $5.52M
    3 analysts

    Next Report

    NXGL has an expected report date of Mar 29, 2027.

    NXGL Earnings Call

    The latest NXGL earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 21 quarters below that had an estimate, NXGL beat 5, missed 15 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $3.18M, up 8.5% from $2.93M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.60-$4.80-$4.80 - -$4.80+66.67%BeatN/A10 up, 1 downNov 10, 2026$3.18M
    Jun 30, 2026-$0.40-$0.12-$0.12 - -$0.12-233.33%MissN/A10 up, 0 downAug 14, 2026$3.69M
    Mar 31, 2026-$0.11-$0.07-$0.07 - -$0.07-57.14%MissN/A10 up, 0 downMay 13, 2026$2.65M
    Dec 31, 2025-$0.15-$0.03-$0.03 - -$0.03-396.00%MissN/A10 up, 1 downMar 31, 2026$2.80M
    Sep 30, 2025-$0.08-$0.08-$0.08 - -$0.080.00%In lineN/A10 up, 1 downNov 11, 2025$2.93M
    Jun 30, 2025-$0.10-$0.07-$0.07 - -$0.07-42.86%MissN/A10 up, 1 downAug 12, 2025$2.88M
    Mar 31, 2025-$0.09-$0.10-$0.10 - -$0.10+10.00%BeatN/A10 up, 0 downMay 13, 2025$2.81M
    Dec 31, 2024-$0.11-$0.10N/A-10.00%MissN/A10 up, 1 downMar 24, 2025$3.04M
    Sep 30, 2024-$0.11-$0.10-$0.10 - -$0.10-10.00%MissN/A11 up, 0 downNov 13, 2024$2.94M
    Jun 30, 2024-$0.15-$0.14-$0.14 - -$0.14-7.14%MissN/A10 up, 0 downAug 19, 2024$1.44M
    Mar 31, 2024-$0.14-$0.18-$0.18 - -$0.18+22.22%BeatN/A10 up, 0 downApr 1, 2024$1.27M
    Dec 31, 2023-$0.21-$0.11-$0.11 - -$0.11-90.91%MissN/A10 up, 0 downMar 18, 2024$1.08M
    Sep 30, 2023-$0.11-$0.12N/A+8.33%BeatN/AN/AN/ANov 13, 2023$1.22M
    Jun 30, 2023-$0.14-$0.13N/A-7.69%MissN/AN/A0 up, 0 downAug 14, 2023$1.17M
    Mar 31, 2023-$0.16-$0.14N/A-14.29%MissN/AN/A0 up, 0 downMay 15, 2023$620000
    Dec 31, 2022-$0.11-$0.15-$0.15 - -$0.15+26.67%BeatN/A10 up, 0 downMar 27, 2023$523000
    Sep 30, 2022-$0.21-$0.13N/A-61.54%MissN/AN/A0 up, 0 downNov 8, 2022$568000
    Jun 30, 2022-$0.19-$0.15-$0.15 - -$0.15-26.67%MissN/A10 up, 0 downAug 10, 2022$561000
    Mar 31, 2022-$0.28-$0.15-$0.15 - -$0.15-86.67%MissN/A10 up, 0 downMay 12, 2022$396000
    Dec 31, 2021-$0.52-$0.37N/A-40.54%MissN/AN/AN/AMar 21, 2022$532000
    Sep 30, 2021-$0.21-$0.20N/A-5.00%MissN/AN/AN/ANov 10, 2021$335000
    Jun 30, 2021-$0.15N/AN/AN/AN/AN/AN/AN/AAug 16, 2021$417000
    Mar 31, 2021-$0.13N/AN/AN/AN/AN/AN/AN/AMay 17, 2021$267000
    Last 23 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.42, after -$0.51 the year before. It was -$1.01 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.42N/A
    Dec 31, 2024-$0.51N/A
    Dec 31, 2023-$0.62N/A
    Dec 31, 2022-$0.79N/A
    Dec 31, 2021-$1.01N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,600 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20262,6336
    2025Q4Dec 31, 20253,7109
    2025Q3Sep 30, 20253,0136
    2025Q2Jun 30, 20254,8667
    2025Q1Mar 31, 20255,0647
    2024Q3Sep 30, 20243,8767
    2024Q2Jun 30, 20242,8176

    2026Q1 Earnings Call

    Opening remarks

    Valter Pinto Managing Director, KCSA Strategic Communications Thank you, operator. Good afternoon, and welcome, everyone, to NEXGEL's shareholder update conference call. I am joined today by Adam R. Levy, Chief Executive Officer. Before we begin, I would like to remind everyone that statements made during today's conference call may be deemed forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of risks, uncertainties, and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to our filings with the SEC filed periodically. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, unless otherwise required by law. With that, it is my pleasure to turn the call over to Mr. Adam R. Levy. Adam, please go ahead.

    Adam R. Levy Chief Executive Officer Thank you, Valter, and thank you, everyone, for joining us today. On today's call, I would like to provide an overview of our first quarter 2026 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we recently closed in mid-April. Starting with our first quarter results, revenue for the first quarter totaled $2.65 million as compared to $2.81 million for the same period last year. The business year-over-year was relatively flat, with sales from Silly George coming in lower, which were partially offset by revenue growth in both contract manufacturing and our MEDAGEL brand. During the quarter, the increase in our SG&A was due primarily to costs incurred relating to the acquisition of our BioNX division and the KISS Nail Products legal case which has since been settled. Cash and restricted cash as of 03/31/2026 was approximately $2.1 million. As of today, our cash on hand is $1.8 million. In total, we have raised $13.8 million comprised of $8.8 million received in cash, and $5 million of our convertible note delivered to Cellularity to fund the acquisition and to provide the business with working capital. The first quarter does not include any revenue from our acquisition. In the second quarter, we have already seen sales from Silly George normalize and recover, and we will begin accounting for revenue from our acquisition for about half of the second quarter. The financing for BioNX was led by Sequence LifeScience, with a $5.5 million investment that not only strengthened the financing structure of the transaction, but also aligns us with a partner that enhances our capabilities across manufacturing, product development, and distribution.

    Frequently Asked Questions About NXGL

    When is Nexgel's next earnings date?

    Nexgel's next earnings report is expected for Mar 29, 2027.

    Did NXGL beat earnings estimates last quarter?

    Yes. Nexgel reported EPS of -$1.60 for the quarter ended Sep 30, 2026, above the -$4.80 estimate, a 66.67% surprise.

    What EPS do analysts expect from NXGL next quarter?

    The consensus EPS estimate for Nexgel for the quarter ending Dec 31, 2026 is -$4.08 from 3 analysts.

    How often does NXGL beat earnings estimates?

    Nexgel beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -82.83%.